Intellect Neurosciences Adds Two New Patent Allowances to Its Global Patent Portfolio and stock prices gone down … All people understood that Big Pharma to give gift shares through broker because they want to buy Intellect for low price ! Buyers are afraid of the fire sale of shares and nobody want to buy the shares ! Since Big Pharma is the dog carrying this bloodsucking ILNS flea, they would like to kill the flea or close it in a box …
Re - john1045 What do you think about the recent report of Pfizer, J&J and Intellect ? These bad news shocked the sick persons and the shareholders ! The reports are too conflicting to each other ... Pfizer, J&J and Intellect VS LINK: http://www.ncbi.nlm.nih.gov/pubmed/22473769
Patients Forty-six patients with mild to moderate Alzheimer disease.
Interventions Patients received either placebo (n = 19) or bapineuzumab (n = 27) in 3 or 4 ascending dose groups. Main Outcome Measures Changes between end of study and baseline in the exploratory CSF biomarkers Aß1-42, AßX-42, AßX-40; total tau (T-tau); and phosphorylated tau (P-tau).
Results Within the bapineuzumab group, a decrease at end of study compared with baseline was found both for CSF T-tau (–72.3 pg/mL) and P-tau (–9.9 pg/mL). When comparing the treatment and placebo groups, this difference was statistically significant for P-tau (P = .03), while a similar trend for a decrease was found for T-tau (P = .09). No clear-cut differences were observed for CSF Aß.
News 
Market Data 
Discover 
